Incretin polyagonists as an alternative to bariatric surgery to manage obesity - PubMed
4 hours ago
- #Obesity treatment
- #Incretin polyagonists
- #Bariatric surgery alternative
- Incretin polyagonists are gut hormone-based drugs that act on multiple receptors (GLP-1, GIP, glucagon) to treat obesity and metabolic dysfunction.
- They provide non-surgical weight loss and metabolic improvements comparable to bariatric surgery, while also enhancing glycemic control, lipid profiles, and cardiovascular risk factors.
- These agents offer a favorable side effect profile and are becoming prominent in clinical guidelines for obesity and type 2 diabetes management, especially for patients unsuitable for surgery.
- Challenges include administration, cost, long-term safety, and accessibility, but ongoing research aims to optimize their role in multidisciplinary obesity care.